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Available online 25 August 2016Background: Population-level monitoring of hepatitis C virus (HCV) infected people across the cascade of care
identiﬁes gaps in access and engagement in care and treatment. We characterized a population-level cascade
of care for HCV in British Columbia (BC), Canada and identiﬁed factors associated with leakage at each stage.
Methods: The BC Hepatitis Testers Cohort (BC-HTC) includes 1.5 million individuals tested for HCV, HIV, reported
cases of hepatitis B, and active tuberculosis in BC from1990 to 2013 linked tomedical visits, hospitalizations, can-
cers, prescription drugs and mortality data. We deﬁned six HCV cascade of care stages: 1) estimated population
prevalence; 2) HCV diagnosed; 3) HCV RNA tested; 4) genotyped; 5) initiated treatment; and 6) achieved
sustained virologic response (SVR).
Results:We estimated that 73,203 people were HCV antibody positive in BC in 2012 (undiagnosed: 18,301, 25%;
diagnosed: 54,902, 75%). Of these, 56%(40,656) had HCV RNA testing; 34%(26,300)were genotyped; 12%( 8532 )
had received interferon-based therapy and 7%(5197) had SVR. Males, older birth cohorts, and HBV coinfected
were less likely to undergo HCV RNA testing. Among those with chronic HCV infection, 32% had received liver-
related care. Retention in liver care was more likely in those with HIV, cirrhosis, and drug/alcohol use and less
likely in males and HBV coinfected.
Conclusions: Although there are gaps in HCV RNA testing and genotyping after HCV diagnosis, the major gap in
the cascade of care was low treatment initiation. People with comorbidities progressed through the cascade of
testing and care but few received treatment.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Treatment1. Introduction
Hepatitis C virus (HCV) is a major global public health problem. Al-
though HCV incidence is declining, morbidity and mortality related to
chronic HCV infection are increasing (Aspinall et al., 2015; Kuo et al.,
2015). In many countries worldwide, the majority of infected individ-
uals acquired the HCVdecades ago, and are now increasingly presenting
with serious liver-related illnesses including decompensated cirrhosis
and hepatocellular carcinoma (Janjua et al., 2015). Potentially curative
interferon based treatments have been available for N15 years, but
b15% of those infected had been treated. HCV cure is associated withre for Disease Control, Clinical
Health, University of British
, Canada.
en access article under the CC BY-NCreduced morbidity and mortality (Simmons et al., 2015; Singal et al.,
2010).
Availability of well-tolerated, short-course (8–12 weeks), interfer-
on-free, direct-acting antiviral (DAA) drugswith cure rates approaching
95% is expected to be a game changer in preventing progressive liver
disease (Smith et al., 2015; Smith and Lim, 2015). However, for these
drugs to have major population-level impact on morbidity and mortal-
ity, screening efforts must reach undiagnosed individuals, diagnosed in-
dividuals must be linked with care and people remain engaged with
care to be assessed for and receive treatment.
The cascade of care has been used to monitor the progress of HIV
programs aimed at reducing the epidemic impact on individuals and
populations (Nosyk et al., 2014). Monitoring the HCV affected popula-
tion across stages of a cascade of care (diagnosis, linkage with care,
treatment, and cure) at a broader population level provides a measure
of program effectiveness and identiﬁes service and access gaps.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
HCV Cascade of Care Deﬁnitions.
1. HCV Prevalence
2012 BC population: 4,542,508
The literature reports a range of 20–44% HCV undiagnosed.
Among linked cohort members alive on Dec. 31, 2012, there were 54,902 HCV
Diagnosed (1.2% of the 2012 BC population)
From this number, we added 25% undiagnosed, or 73,203 anti-HCV positive
persons living in BC in 2012 (1.6% of the 2012 BC population)
2. HCV Diagnoseda
On or before Dec. 31, 2012:
• a conﬁrmed anti-HCV positive test
• a conﬁrmed HCV RNA positive test
• an HCV genotype result
• dispensation of interferon-based antivirals
• a conﬁrmed public health HCV case report
3. HCV RNA Tested
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to policy makers for forecasting budgetary impacts of treatment
with very expensive drugs. The HCV cascade of care has been pre-
sented for speciﬁc population groups such as US veterans or small
community programs for people who inject drugs (PWID) but not
for an overall population (Maier et al., 2016; Viner et al., 2015;
Wade et al., 2015).
In British Columbia (BC), DAAs became available in 2014 and are
publicly-funded for people with advanced liver disease (≥F2 METAVIR
or equivalent). The data presented in this paper based on all tested
and diagnosed individuals in BC characterized the population-level
HCV cascade of care in BC, Canada, and identiﬁed factors associated
with leakage at each stage. This provides a population-based bench-
mark for monitoring the progress of hepatitis care programming to
guide policy in British Columbia which can also be used as a framework
for other jurisdictions internationally.At least one HCV RNA (PCR) test on record on or before Dec. 31, 2012
3a. HCV RNA Negative
Among HCV Diagnosed individuals with no dispensation of interferon-based
antivirals (untreated), the last HCV RNA test on record on or before Dec. 31, 2012 is
negative. These individuals are considered not actively infected/non-viraemic
4. HCV Genotyped
At least one valid genotype test result on record on or before Dec. 31, 2012
5. Initiated HCV Antiviral Treatment
Dispensation, on or before Dec. 31, 2012, of interferon-based antivirals speciﬁc to
HCV treatmentb
6. Estimated SVRc
Among treated individuals:
• in those with HCV RNA testing results between 12 and 52 weeks after the last
drug dispensation on record, HCV RNA testing is persistently negative or the last
two HCV RNA results are negative
• in those without HCV RNA testing results between 12 and 52 weeks after the last
dispensation, HCV RNA testing results after 52 weeks are persistently negative
NB: 1361(16.0%) treated individuals lacked adequate HCV RNA data in the timeframe of
interest to be assessed for SVR.
a Earliest available laboratory testing data (1992), reportable disease data (1990), and
drug dispensation data (2000).
b Drug Information Number/Product Identiﬁcation Number (DINPIN): 2254603,
2254638, 2254646, 2371448, 2371456, 2371464, 2371472, 2371553, 2370816, 2241159,
2239730, 2246030, 2246028, 2246029, 2246027, 2246026, 2253410, 2253429, 2254581.2. Methods
2.1. Setting
The study presents data from the province of BC, Canada. All resi-
dents of BC are registered in publicly funded Medical Services Plan
(MSP) that act as a single payer system and covers services provided
by fee for service practitioners including general practices, private labo-
ratories and other fee for service providers. HCV laboratory testing for
the entire province is centralized at BC Public Health Laboratory
(BCPL) except for b5% of tests performed at a regional laboratory
which sends positive tests to BCPHL for conﬁrmation. Prescription
drugs are either covered by public program for eligible patients or by
their private extended health insurance which is usually provided by
employers. All dispensed prescriptions are recorded in central system
called PharmaNet. Interferon-based combination therapies (Interfer-
on/Ribavirin) for HCV treatment were ﬁrst publicly funded in 2000
and themore efﬁcacious Pegylated interferon/Ribavirin therapy became
available in May 2003.c HCVRNA data up to Dec. 31st, 2013was included to allow assessment of SVR for 2012
treatment starts.2.2. The Cohort
We used data from the BC Hepatitis Testers Cohort (BC-HTC). The
BC-HTC construction and data linkage has been described elsewhere
(Janjua et al., 2016a; Janjua et al., 2016b). Brieﬂy, the BC-HTC includes
all individuals tested for HCV or HIV, or reported as a case of HBV,
HCV, HIV or active tuberculosis (TB) in BC between 1990 and 2013
linked with data on medical visits, hospitalizations, cancers, prescrip-
tion drugs, and deaths (BC Vital Statistics Agency, 2014; British
Columbia Ministry of Health, 2014a,b,c,d,e). For this evaluation of the
HCV cascade of care, individuals had to be alive on December 31st,
2012 and HCV diagnosed on or before December 31st, 2012. This
study was approved by the University of British Columbia Research
Ethics Board (H14-01649).2.3. Cascade of Care
We used the 2012 BC population estimate (4,542,508 persons) as
the denominator for prevalence calculations (Stats, 2012). Table 1 pro-
vides operational deﬁnitions for six stages of theHCV cascade of care: 1)
estimated population prevalence; 2) HCV diagnosed; 3) HCV RNA test-
ed; 4) genotyped; 5) initiated antiviral treatment; and 6) sustained vi-
rologic response (SVR). Genotyping was used as proxy for linkage
with HCV care, though this may change with streamlined testing cas-
cade. We applied these deﬁnitions to the data to estimate the number
and proportion of individuals in each stage.2.4. Estimate of Viraemia
The estimate of actively infected persons in BC in 2012wasbased on:
1) the number of untreated individuals in which the last HCV RNA test
on record is positive; 2) 75% of those who were positive by antibody
testing and had no HCV RNA or genotype testing done as about 25% of
antibody positive individuals clear infection spontaneously; 3) 75% of
the untested and undiagnosed estimate; 4) those treated individuals
determined not to have achieved SVR.2.5. Characteristics of HCV Diagnosed and those with and without RNA
Testing or Genotyping
Wedescribed the demographic characteristics and comorbidity pro-
ﬁle of HCV diagnosed including: individuals with andwithout RNA test-
ing; and RNA positive individuals with and without HCV genotyping.
Demographic characteristics included sex, age in 2012, birth cohort
(b1945, 1945–1964, 1965–1974, ≥1974), and social andmaterial depri-
vation quintiles (Pampalon et al., 2009). Comorbidity indicators were
derived from MSP data containing physician fee-for-service billing and
diagnostic codes, and hospitalization data for mental health diagnoses,
problematic alcohol and drug use, recent hospitalization, Elixhauser co-
morbidity index, cirrhosis, and decompensated cirrhosis (Supplement-
Table 1) (Kramer et al., 2008; Lo Re et al., 2011; McDonald et al., 2010;
Nehra et al., 2013). We assessed factors associated with not having
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regression modeling.2.6. Engagement with Care
Engagement in liver related care was deﬁned as at least onemedical
visit to a gastroenterologist, infectious disease specialist, internal medi-
cine specialist, or general/family practitioner for a liver-related diagnos-
tic code or fee item(including tests for monitoring liver function); or a
liver-related hospitalization; or a liver biopsy; or HCV genotyping or
current HCV treatment (Supplement-Table 2).
To assess 2012 levels of healthcare engagement among known pos-
itives, we excluded subjects known to be HCV RNA negative at the last
HCV RNA test on record and those with inadequate follow-up time (b-
12months) during themost recent two years of data, 2011–2012, or di-
agnosis on or after January 1st, 2012. To better distinguish those not
attending primary care from those who may have out-migrated from
theprovince, we excluded individualswhohad no record in theMSP cli-
ent roster and no medical visits or hospitalization from 2007 to 2012.
Those remaining are most likely to be viraemic and still requiring as-
sessment for treatment.We then assessedmedical visit and hospitaliza-
tion records in 2011–2012 to determine and categorize individuals as:
1) retained in liver-related care; 2) retained in primary healthcare but
not liver-related care; or 3) not retained in primary healthcare. We
compared characteristics of those retained in primary care, and those
not retained in care with those retained in liver-related care in 2011–
12 by multinomial logistic regression modeling.Table 2
Characteristics associated with lack of HCV RNA testing among HCV Diagnosed individuals in B
All HCV Diagnosed HCV RNA Tested
n (%) n (%)
n (row %)b 54,902 (100) 40,656 (74.1)
Sex
Male 35,430 (64.5) 25,692 (63.0)
Female 19,472 (35.5) 15,027 (37.0)
Birth Cohort
b1945 3252 (5.9) 2181 (5.4)
1945–1964 33,738 (61.5) 25,035 (61.6)
1965–1974 11,659 (21.2) 8451 (20.8)
≥1975 6253 (11.4) 4989 (12.3)
HIV/AIDS Coinfection
Yes 3178 (5.8) 2605 (6.4)
No/Unknown 51,724 (94.2) 38,051 (93.6)
HBV Coinfection
Yes 2104 (3.8) 1346 (3.3)
No/Unknown 52,798 (96.2) 39,310 (96.7)
Active TB
Yes 292 (0.5) 232 (0.6)
No/Unknown 54,610 (99.5) 40,424 (99.4)
Major Mental Health Diagnosis
Yes 16,550 (30.1) 13,135 (32.3)
No/Unknown 38,352 (69.9) 27,521 (67.7)
Problematic Alcohol Use
Yes 19,624 (35.7) 14,895 (36.6)
No/Unknown 35,278 (64.3) 25,761 (63.4)
Illicit Drug Use
Yes 28,243 (51.4) 21,269 (52.3)
No/Unknown 26,659 (48.6) 19,387 (47.7)
Material Deprivation Quintilec
Q1 (most privileged) 7006 (12.8) 5425 (13.3)
Q2 8347 (15.2) 6268 (15.4)
Q3 9557 (17.4) 7213 (17.7)
Q4 12,086 (22.0) 9133 (22.5)
Q5 (most deprived) 15,665 (28.5) 11,591 (28.5)
Unknown 2241 (4.1) 1026 (2.5)
a Adjusted for all covariates listed in multivariable logistic regression.
b All percentages displayed are column percent, except for the ﬁrst row, which is row perce
c At the time of diagnosis.2.7. Role of the Funding Source
The BC Centre for Disease Control supported construction of the BC-
HTC to inform policy and program related to HCV in British Columbia.
The funders of the study had no role in study design, data analysis,
data interpretation, or writing of the article. NJ has full access to all the
data in the study andmade decision to submit the paper for publication.
3. Results
3.1. Estimated HCV Population Distribution across Cascade of Care
There were 54,902 HCV diagnosed individuals alive by the end of
2012, 1.2% of the 2012 BC population (Table 1). Although literature
and national modeling estimates suggest that 20–44% of HCV infections
remain undiagnosed in Canada (Trubnikov et al., 2014), because of high
HCV testing rates in BC and declining positivity among baby boomers
(born 1945–64), (Janjua et al., 2016b; Consolacion et al., 2015) we
used an undiagnosed estimate of 25%, bringing the anti-HCV prevalence
in BC in 2012 to 73,203(1.6% of the population). Of these, 56% (40,656)
had at least one HCV RNA test; 36% (26,300) had genotype testing; 12%
(8532) had been dispensed treatment; and 7% (5197) were estimated
to have achieved SVR (Fig. 1).
3.2. Diagnosed and Tested Subjects across the Cascade of Care
Of 54,902HCV diagnosed individuals alive at the end of 2012, 40,656
(74%) had at least one HCV RNA test on record. Among these, 9842C, Canada, 1992–2012.
Not HCV RNA Tested Unadjusted
OR (95% CI)
Adjusteda
OR (95% CI)
n (%)
14,246 (25.9)
9801 (68.8) 1.29 (1.24,1.35) 1.23 (1.18,1.28)
4445 (31.2) ref ref
1071 (7.5) 1.94 (1.76,2.13) 1.88 (1.70,2.07)
8703 (61.1) 1.37 (1.28,1.47) 1.34 (1.25,1.44)
3208 (22.5) 1.50 (1.39,1.61) 1.49 (1.38,1.61)
1264 (8.9) ref ref
573 (4.0) 0.61 (0.56,0.67) 0.63 (0.57,0.69)
13,673 (96.0) ref ref
758 (5.3) 1.64 (1.50,1.80) 1.67 (1.52,1.83)
13,488 (94.7) ref ref
60 (0.4) 0.84 (0.64,1.10) 0.99 (0.75, 1.30)
14,186 (99.6) ref ref
3415 (24.0) 0.66 (0.63,0.69) 0.70 (0.67,0.73)
10,831 (76.0) ref ref
4729 (33.2) 0.86 (0.83,0.90) 0.96 (0.92,1.01)
9517 (66.8) ref ref
6974 (49.0) 0.87 (0.84,0.91) 1.08 (1.03,1.13)
7272 (51.0) ref ref
1581 (11.1) ref ref
2079 (14.6) 1.01 (0.94,1.08) 1.00 (0.94,1.08)
2344 (16.5) 1.01 (0.95,1.09) 1.01 (0.94,1.08)
2953 (20.7) 1.11 (1.04,1.19) 1.10 (1.02,1.17)
4074 (28.6) 0.98 (0.91,1.05) 0.99 (0.92,1.06)
1215 (8.5) 2.52 (2.30,2.76) 2.46 (2.24,2.69)
nt
Fig. 1. HCV Cascade of Care as of 31-Dec-2012, British Columbia, Canada. Arrows between bars represents the proportion of patients in each step of the cascade from the patients in the
preceding step. E.g., 32% of those genotyped initiated HCV treatment.
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no treatment, and 30,814 (76%) had a positive HCV RNA test. Among
HCV RNA positive individuals, 26,300 (85%) had been genotyped. Of
the 8532 individuals who initiated treatment, 5197(61%) had a SVR;
1974 (23%) failed treatment; and 1461(17%) lacked available HCV
RNA testing records to assess treatment outcome (Fig. 1).
3.3. Estimated Population Prevalence of Active Infection
We estimated 50,027 persons were actively infected in 2012: 1)
22,282 untreated individuals with HCV RNA testing on record, in
which the last HCV RNA test on record remained positive; 2) 75%
(10,684) of 14,246, who were positive by antibody testing only (no
HCV RNA on record); 3) 75% (13,726) of the 18,301 undiagnosed esti-
mate; and 4) 3335 treated individuals who did not achieved SVR.
3.4. Characteristics of HCV Diagnosed
Almost two-thirds of the 54,902 HCV diagnosed individuals were
male. Sixty-two percent were born 1945–1964 with an additional 6%
born before 1945, thus, two-thirds are currently 50 years of age or
older (Table 2). Prevalence of HIV, HBV and active TB coinfection was
5.8%, 3.8%, and 0.6%, respectively. The proportion with a history of a
majormental health diagnosis was high (30%), aswas problematic alco-
hol (36%) and drug use (51%).
Three-quarters of HCV diagnosed had at least one HCV RNA test on
record, and males had higher odds than females of not being HCV RNA
tested (adjusted odds ratio (AdjOR) = 1.23; 95%CI:1.18,1.28) (Table
2). As compared to the youngest birth cohort(born ≥1975), older birth
cohorts were less likely to be HCV RNA tested and those born before
1945 were least likely to have RNA testing. Those with HIV coinfection
were more likely to be tested for RNA (AdjOR = 0.63, 95%CI:
0.57,0.69) while those with HBV coinfection were more likely to lack
RNA testing (AdjOR = 1.67; 95%CI:1.52,1.83).
Among the 30,841 HCV RNA positive people, 85% underwent
genotyping (Supplement Table 3). Those born 1945–64 were the mostlikely to be genotyped. HIV coinfection remained associated with mov-
ing forward in the testing continuumwhile those with HBV coinfection
were slightly less likely to be genotyped. Drug use history was associat-
ed with a higher odds of not being genotyped (AdjOR = 1.17;
95%CI:1.09, 1.22) as were those in the lowest socioeconomic quintile.
3.5. Retention in Healthcare and HCV-Related Care
31,511 individuals, known to be HCV positive at the last test on re-
cord and eligible for the analysis based on adequate follow-up time
were assessed for retention in the healthcare system and liver-related
care during the 2011–2012 (Table 3). Of these, 10,083(32%) were
found be retained in liver-related care; 17,358(55%) were found to be
retained in primary healthcare but not in liver-related care; and
4070(13%) had no physician or hospital visits in the two year period,
suggesting lack of retention in any care. The 31,511 individuals assessed
were predominantly older andmale, with over half falling in the lowest
two material deprivation quintiles. As expected due to shorter follow-
up time, recent mental health and substance use indicators were
lower than lifetime history, particularly for alcohol. However, 32% of
this group experienced a hospitalization in 2011–2012 and one-third
had a least one comorbidity.
In multivariable model (Table 4), compared to those retained in
liver-related care, those retained in primary care only were more likely
to be female, older, and HBV coinfected. Those with HIV, cirrhosis, or
drug use were more likely to be in liver care. Compared to those in
liver care, those not retained in any care in 2011–12 had higher odds
of beingmale, HBV co-infected and born in 1965–1974 (Table 4). People
with HIV, cirrhosis, mental illness, alcohol, and drug usewere less likely
to be not in any care.
In those with a least one treatment dispensation (n= 8532), most
(73%) were born in 1945–1964 (Table 3). Small proportion of HIV
(4.8%) and HBV (2.8%) coinfected individuals were ever dispensed
treatment. While 10% of those in liver-related monitoring or care are
HIV coinfected, this was 5% in the dispensed treatment group. Of 2094
HCV RNA positive individuals who were also HIV positive, 408(20%)
Table 3
Retention in Healthcare and Liver-Related Care among HCV positive individuals, BC, Canada, in 2011–2012.
Individuals Requiring Ongoing Liver Monitoring and Care Ever Dispensed HCV Treatmenta
Eligible for Evaluation Retained in Liver Care Retained in Primary Care Not Retained in any Care
n (row %)b 31,511 (100) 10,083(32.0) 17,358(55.1) 4070 (12.9) 8532 (100)
Sex
Female 10,757 (34.1) 3437 (34.1) 6147 (35.4) 1173 (28.8) 2762 (32.4)
Male 20,754 (65.9) 6646 (65.9) 11,211 (64.6) 2897 (71.2) 5770 (67.6)
Age in 2012
b15 72 (0.2) 19 (0.2) 36 (0.2) 17 (0.4) 2 (0.02)
15–24 252 (0.8) 84 (0.8) 136 (0.8) 32 (6.7) 22 (0.3)
25–34 1906 (6.1) 819 (8.1) 815 (4.7) 272(19.0) 327 (4.1)
35–44 5189 (16.5) 1808 (17.9) 2606 (15.0) 775 (36.7) 1006 (11.8)
45–54 10,312 (32.7) 3169 (31.4) 5649 (32.5) 1494 (36.7) 2393 (28.1)
≥55 13,780 (43.7) 4184 (41.5) 8116 (46.8) 1480 (36.4) 4782 (56.1)
Birth Cohort
b1945 1828 (5.8) 450 (4.5) 1174 (6.8) 204 (5.0) 501 (5.9)
1945–1964 19,744 (62.7) 6109 (60.6) 11,275(65.0) 2360 (58.0) 6184 (72.5)
1965–1974 6624 (21.0) 2211 (21.9) 3394 (19.6) 1019 (25.0) 1275 (14.9)
≥1975 3315 (10.5) 1313 (13.0) 1515 (8.7) 487 (12.0) 572 (6.7)
HIV/AIDS Coinfection 1882 (6.0) 957 (9.5) 778 (4.5) 147 (3.6) 408 (4.8)
HBV Coinfection 1074 (3.4) 300 (3.0) 631 (3.6) 143 (3.5) 236 (2.8)
Active TB 170 (0.5) 69 (0.7) 90 (0.5) 11 (0.3) 27 (0.3)
Major Mental Health Diagnosis
Ever 10,217 (32.4) 3652 (36.2) 5722 (33.0) 843 (20.7) 2557 (30.0)
Recent (2011−2012) 3488 (11.1)a 1667 (16.5) 1821 (10.5) unable to evaluate unable to evaluate
Problematic Alcohol Use
Ever 12,342 (39.2) 4281 (42.5) 6869 (39.6) 1192 (29.3) 2476 (29.0)
Recent (2011–2012) 2293 (7.3)a 996 (9.9) 1297 (7.5) unable to evaluate unable to evaluate
Illicit Drug Use
Ever 17,486 (55.5) 6072 (60.2) 9535 (54.9) 1879 (46.2) 3468 (40.7)
Recent (2011–2012) 7371 (23.4)a 3299 (32.7) 4072 (23.5) unable to evaluate unable to evaluate
Recent Hospitalization (2011–2012) 10,116 (32.1)a 4419 (43.8) 5697 (32.8) unable to evaluate unable to evaluate
Elixhauser Comorbidity Index (2008–2012)
0 20,883 (66.3) 5701 (56.5) 11,581(66.7) 3601 (88.5) n/a
1–2 7077 (22.5) 2762 (27.4) 3995 (23.0) 320 (7.9) n/a
3–4 2435 (7.7) 1110 (10.9) 1222 (7.0) 113 (4.6) n/a
4+ 1116 (3.5) 520 (5.2) 560 (3.2) 36 (0.9) n/a
Cirrhosis (Ever) 1753 (5.6) 850 (8.4) 759 (4.4) 144 (3.5) 861 (10.1)
Decompensated Cirrhosis (Ever) 951 (3.0) 473 (4.7) 388 (2.2) 90 (2.2) 429 (5.0)
2012 Material Deprivation Quintile
Q1 (most privileged) 4068 (12.9) 1380 (13.7) 2184 (12.6) 504 (12.4) 1234 (14.5)
Q2 4861 (15.4) 1498 (14.9) 2750 (15.8) 613 (15.1) 1413 (16.6)
Q3 5699 (18.1) 1722 (17.1) 3246 (18.7) 731 (18.0) 1647 (19.3)
Q4 7223 (22.9) 2321 (23.0) 3947 (22.7) 955 (23.5) 1950 (22.9)
Q5 (most deprived) 9144 (29.0) 2973 (29.5) 5020 (28.9) 1151 (28.3) 2193 (25.7)
Unknown 516 (1.6) 189 (1.9) 211 (1.2) 116 (2.9) 95 (1.1)
2012 Social Deprivation Quintile
Q1 (most privileged) 3226 (10.2) 1015 (10.1) 1799 (10.4) 412 (10.1) 1209 (14.2)
Q2 3922 (12.5) 1244 (12.3) 2197 (12.7) 481 (11.8) 1340 (15.7)
Q3 5274 (16.7) 1654 (16.4) 2973 (17.1) 647 (15.9) 1574 (18.5)
Q4 6686 (21.2) 2090 (20.7) 3792(21.9) 804 (19.8) 1754 (20.6)
Q5 (most deprived) 11,887 (37.7) 3891 (38.6) 6383 (36.8) 1610 (39.6) 2560 (30.0
Unknown 516 (1.6) 189 (1.9) 211 (1.2) 116 (2.9) 95 (1.1)
Treated subjects were alive (no death record) as of 31-Dec.-2012 and had a least one dispensation record for an eligible HCV pharmacotherapy drug prior to 2013.
a Note that treated subjects are appended for comparison but most were not eligible for the retention evaluation and some measures cannot be compared.
b All percentages displayed are column percent, except for the ﬁrst row, which is row percent.
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low proportion of individuals with a history illicit drug use.
4. Discussion
This population-based study characterized the cascade of HCV care
in British Columbia, Canada. A large proportion of antibody positive per-
sons received HCV RNA testing (75%) and subsequent genotyping
(80%). In recent years, HCV RNA testing has increased to N80% of
those diagnosed. However, only a small proportion initiated HCV treat-
ment and were subsequently cured. Males, older birth cohorts, and
thosewith HBV coinfectionwere less likely to undergo HCV RNA testing
while those with a history of illicit drug use were less likely to be geno-
typed. People with HIV, cirrhosis, problem drug or alcohol use were
more likely to be in liver care while males and those with HBV coinfec-
tion were less likely to be retained in care. In summary, most peoplemoved along the testing continuum, but retention in care and treatment
initiation were major gaps. People with major comorbidities have been
more engaged in the testing continuum, but fewhad initiated treatment
in the interferon era. These ﬁndings have important implications for
HCV prevention, care and treatment programs.
We demonstrated that linked administrative datasets that integrate
data from various sources similar to the BC-HTC could be used to mon-
itor the progress of HCV infected individuals across the cascade of care
to assess program effectiveness in providing services at various stages
of the cascade. We identiﬁed characteristics (demographic, comorbidi-
ties, co-infections, socioeconomic and geographic disparities) of HCV
patients who did not progress to the next stage of care that could be
used to realign services and programs to target individuals not
progressing and falling behind along the cascade. The cascade was
presented at the provincial level but is replicable for regions within BC
to assess local program progress to inform interventions for
Table 4
Multivariablemultinomial logistic regressionmodel of factors associatedwith retention in
Primary Care or No Care compared to those retained in liver-related care among eligiblea
HCV Positive individuals, BC, Canada, in 2011–2012.
Primary Care
n= 17,358 (55.1% )
No Care
n= 4070 (12.9%)
Adj OR (95%CI) Adj OR (95%CI)
Sex
Male vs. Female 0.93(0.89–0.99) 1.27(1.17–1.38)
Birth Cohort (ref ≥ 1975)
b1945 2.21(1.93–2.53) 0.92(0.76–1.13)
1945–1964 1.62(1.49–1.76) 0.94(0.84–1.06)
1965–1974 1.37(1.25–1.50) 1.30(1.15–1.49)
HIV/AIDS Coinfection
Yes vs. No/Unknown 0.48(0.44–0.53) 0.43(0.35–0.51)
HBV Coinfection
Yes vs. No/Unknown 1.30(1.13–1.50) 1.31(1.07–1.61)
Illicit Drug Use
Yes vs. No/Unknown 0.93(0.87–0.98) 0.71(0.65–0.77)
Cirrhosis
Yes vs. No/Unknown 0.45(0.40–0.50) 0.43(0.36–0.51)
Material Deprivation Index (ref Q1/most privileged)
Q2 1.15(1.05–1.27) 1.13(0.98–1.30)
Q3 1.19(1.08–1.30) 1.18(1.03–1.35)
Q4 1.09(1.00–1.19) 1.16(1.02–1.32)
Q5 1.10(1.01–1.19) 1.13(0.99–1.27)
Unknown 0.73(0.59–0.90) 1.59(1.23–2.06)
Major Mental Health Diagnosis
Yes vs. No/Unknown 0.95 (0.89–1.00) 0.58(0.53–0.64)
Problematic Alcohol Use
Yes vs. No/Unknown 1.02(0.96–1.08) 0.77(0.71–0.84)
a As per Table 3, there were 31,511 persons eligible for evaluation of retention in care.
They were categorized as retained in liver-related monitoring or care; primary care; no
care. The referent group is those retained in liver monitoring or care (n = 10,083) (32%).
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guide the policy to achieve the World Health Organization's goal of
HCV elimination (World Health Organization, 2016).
Although, HCV RNA and genotype testing rates have improved in re-
cent years and are similar to those reported for HCV positive Veterans
and Kaiser Permanente members in the United States (95%) and higher
than for primary care in Canada and United States (47.0% to 60.9%),
there is a further need to reduce the gap between those antibody diag-
nosed and those undergoing further testing (Maier et al., 2016; Jonas et
al., 2016; Spradling et al., 2014; Viner et al., 2015). We demonstrated
that people with high risk activities progress to RNA testing while
men and older cohorts, especially those born in 1945–64 lacked RNA
testing (Spradling et al., 2014; Cachay et al., 2014). A major factor for
lack of genotyping among those RNA tested was history of drug use.
Data from Canada and other countries suggest that lack of knowledge
among primary care physicians, especially those not involved in provid-
ing care to those with known risk activities, regarding next steps in the
cascade and poor knowledge among patients are associated with the
gap from HCV diagnosis to RNA testing (Butt et al., 2013; Grebely et
al., 2013; Guirgis et al., 2012). Although guidelines and education for
primary care physicians are important instruments to bridge this gap,
a single blood sample test strategy in which those testing positive for
antibody are also tested for RNA (reﬂex testing) and possibly for geno-
type could be an effective structural intervention to bridge this gap. Re-
ﬂex testing for RNA has been implemented in the VA system and
recently in Kaiser Permanente system, and was associated with higher
RNA testing rates (Maier et al., 2016; Jonas et al., 2016).
Despite a robust testing continuum for those accessing screening, BC
remains similar to the US, Australia and other countries in initiating
treatment (Maier et al., 2016; Viner et al., 2015; Lazarus et al., 2014;
Hajarizadeh et al., 2016). We found that a small proportion (15%) of
HCV diagnosed individuals initiated HCV treatment by 2012. Those
who did not progress to treatment, even while in liver care included
those with HIV coinfection and people currently engaged in illicit drug
use. Factors related to poor tolerability and efﬁcacy of interferon basedtreatments alongwith other factors at the patient (poor knowledge, un-
employment, competing priorities, stigma, lack insurance and provider
relationship), provider (perception of poor adherence, ongoing sub-
stance use, psychiatric illness, potential re-infection) and, system (lack
of consensus on screening and treatment and coverage of HCV treat-
ments) levels have been reported to be associatedwith lower treatment
rates in these populations in Canada and other settings (Grebely et al.,
2013; Aspinall et al., 2013). DAAs are expected to overcome some of
these barriers, though high drug costs may affect reimbursement
coverage.
Thosewith HBV coinfectionwere less likely to have HCV RNA testing
and thus be aware of their HCV infection status; and be retained in any
liver-related monitoring or care. The inability to move forward in the
initial testing stages of the HCV cascade of care precludes being offered
treatment, as also seen in the low numbers of HBV positive persons dis-
pensed treatment. Chronic HBV is more common in immigrants from
HBV endemic countries. Further characterization of HCV-HBV coinfec-
tion is needed, including evaluation by ethnicity, to clarify factors relat-
ed to lack of RNA testing and progression in the HCV cascade of care.
Immigrants from HCV endemic countries have a high burden of HCV
but data on the current burden in BC is limited. Characterization of bur-
den and assessment of progression across the cascade of care among
immigrants is needed.
Despite comprehensive data available to us for characterization of
the cascade of care, there are several limitations that impact each
stage. The estimate of prevalent HCV cases is based on the number of
HCV undiagnosed cases derived in a national model based on reported
cases and survey data (Trubnikov et al., 2014). Historically, BC has test-
edmore individuals for HCV(by December 2014, 33% of BC's population
has been tested at least once) than other provinces and in recent years
testing volumes have increase substantially, suggesting our undiag-
nosed proportion may be lower than the national average
(Consolacion et al., 2015). We have also seen decline in HCV positivity
among baby boomers from 13% in 2001 to 2% in 2013, suggesting de-
clining pool of undiagnosed individuals in BC (Janjua et al., 2016b). All
these data suggest lower percentage of undiagnosed individuals in BC
than national average. In our evaluation of those requiring ongoing
monitoring and care, we excluded those with patterns suggesting
outmigration. While unlikely, a small proportion of these people may
still be in the province but not accessing care. We used diagnostic
codes in administrative datasets to assess history of mental illness and
substance use. This raisesmultiple issues: bias towards underestimating
prevalence in those less engaged in healthcare, and potential misclassi-
ﬁcation related to sensitivity and speciﬁcity of these measures. Poten-
tially lower linkage rates in vulnerable groups would result in less
representation of homeless, street-involved, and incarcerated individ-
uals (Janjua et al., 2016a).
We have demonstrated the utility of the BC-HTC integrating data
from various sources to monitor the progress of HCV infected individ-
uals across the cascade of care, which will inform reﬁnement in pro-
grams and policies in British Columbia to optimize HCV response
within the context of a changed treatment landscape. Similar systems
could be established in other jurisdictions tomonitor programprogress.
In BC, HCV infected individuals; especially those with high risk condi-
tions, progressed well through the testing continuum and also had
liver monitoring, though some gaps remain. The major gap in the HCV
cascade of care remains treatment initiation. Efforts are needed to esti-
mate the number of undiagnosed individuals, and to assess cost effec-
tiveness of various screening options to inform the optimal screening
strategy. Implementation of reﬂex RNA testingwould bridge the gap be-
tweenHCVdiagnosis and conﬁrmation of active infection. There is also a
need to link older populationswithmultiple comorbidities and a second
group of younger, less engaged persons into care. BC needs to work
across multiple levels of the healthcare system to deﬁne the supports
required to link into care thosewho remain unassessed aswell as to ex-
pand capacity to assess and treat in a variety of settings.
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